TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24097422

Group type: EXPERIMENTAL
Intervention: Modified Blalock‐Taussig shunt
Number of subjects: 549

Group type: COMPARATOR
Intervention: RV‐to‐pulmonary artery shunt
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: Pre-Norwood to pre-stage II
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: Pre-stage II to 14 months
Number of subjects: 549
Study: 21565530

Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg at the induction of anesthesia and at the initiation of CPB)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 117
Study: 19782621

Group type: EXPERIMENTAL
Intervention: Coronectomy
Number of subjects: 231

Group type: COMPARATOR
Intervention: Total excision (Control)
Number of subjects: 231
Study: 16826092

Group type: EXPERIMENTAL
Intervention: Cemented stem fixation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Press-fit stem fixation
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study: 14656250

Group type: EXPERIMENTAL
Intervention: 1 mg vitamin B12
Number of subjects: 28

Group type: COMPARATOR
Intervention: 1 mL saline placebo
Number of subjects: 28
Study: 11429358

Group type: EXPERIMENTAL
Intervention: 3 mg IV nalbuphine (n = 91)
Number of subjects: 181

Group type: COMPARATOR
Intervention: 20 mg IV propofol (n = 90)
Number of subjects: 181
Study: 9744436

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 7998585

Group type: EXPERIMENTAL
Intervention: Rilmenidine 1 mg orally daily (Group 1)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Rilmenidine 1 mg every other day (Group 2)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Rilmenidine 1 mg at the end of each dialysis session (Group 3)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Rilmenidine 1 mg daily (Group 1)
Number of subjects: 38
Study: 3377142

Group type: EXPERIMENTAL
Intervention: Inhaled dipyridamole
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control solution
Number of subjects: 13
Study: 31205187

Group type: EXPERIMENTAL
Intervention: PF‐02545920 5 mg
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: PF‐02545920 15 mg
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study: 28593920

Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL)
Number of subjects: 46
Study: 26649542

Group type: EXPERIMENTAL
Intervention: Auditory training (AT) group (hearing aids + 3 week remotely delivered, Internet‐based auditory training program)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (hearing aids alone)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Auditory training (AT) group
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 29
Study: 23752717

Group type: EXPERIMENTAL
Intervention: Knowledge of Procedure (KP)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Knowledge of Result (KR)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 30
Study: 21993041

Group type: EXPERIMENTAL
Intervention: DMOI bat training (n = 9)
Number of subjects: 17
Study: 19748406

Group type: EXPERIMENTAL
Intervention: Spinal manipulative therapy (SMT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Detuned ultrasound (placebo)
Number of subjects: 30
Study: 16485227

Group type: EXPERIMENTAL
Intervention: Blue light filtering IOL (SN60AT, Alcon)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Conventional single‐piece IOL (SA60AT, Alcon)
Number of subjects: 14
Study: 15483411

Group type: EXPERIMENTAL
Intervention: Albumin administration
Number of subjects: 3782

Group type: COMPARATOR
Intervention: No albumin (control group)
Number of subjects: 3782

Group type: COMPARATOR
Intervention: Low-dose albumin (control group)
Number of subjects: 3782

Group type: COMPARATOR
Intervention: Moderate-dose albumin (control group)
Number of subjects: 3782
Study: 10376237

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 9081352

Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI) at a dose of 33 Gy/11 fractions (45 patients) and 25 Gy/11 fractions (112 patients)
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI)
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Patients with the best prognosis receiving PCI
Number of subjects: 257

Group type: COMPARATOR
Intervention: Patients with the best prognosis not receiving PCI
Number of subjects: 257

Group type: COMPARATOR
Intervention: Delayed late chest irradiation (LCI)
Number of subjects: 257
Study: 1670734

Group type: EXPERIMENTAL
Intervention: Aspirin taken at least once during the week before the first symptom
Number of subjects: 875

Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 875

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 875

Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 875

Group type: EXPERIMENTAL
Intervention: Piroxicam
Number of subjects: 875

Group type: EXPERIMENTAL
Intervention: Paracetamol, propyphenazone, and dipyrone
Number of subjects: 875
Study: 6339708

Group type: EXPERIMENTAL
Intervention: Single-dose amoxicillin therapy
Number of subjects: 49

Group type: COMPARATOR
Intervention: Conventional therapy (10-day course of amoxicillin)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Antibody-coated bacteria assay
Number of subjects: 49
Study: 31864884

Group type: EXPERIMENTAL
Intervention: Survey on pharmacists' attitudes and current practice regarding their role in preconception, pregnancy, and lactation counseling.
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Survey on barriers to counseling during preconception, pregnancy, and lactation.
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Knowledge test administered to pharmacists.
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Mystery shopping scenarios including requests for pregnancy tests and OTC products for pregnancy-related nausea.
Number of subjects: 63
Study: 29742744

Group type: EXPERIMENTAL
Intervention: Self-Myofascial Release (SMR)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Instrument-Assisted Soft-Tissue Mobilization (IASTM)
Number of subjects: 49
Study: 31462477

Group type: EXPERIMENTAL
Intervention: 14-week PEERS group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Waitlist care as usual group
Number of subjects: 40
Study: 28426350

Group type: EXPERIMENTAL
Intervention: Lenalidomide maintenance 25 mg/d for 21 days of every 28-day cycle for 24 months
Number of subjects: 650

Group type: COMPARATOR
Intervention: Placebo for 24 months
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Lenalidomide maintenance
Number of subjects: 650

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 650
Study: 25488331

Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine (LAIV)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Inactivated influenza vaccine (IIV)
Number of subjects: 10
Study: 23384237

Group type: EXPERIMENTAL
Intervention: Online health behavior intervention (U@Uni)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study: 21701174

Group type: COMPARATOR
Intervention: Methylphenidate + Levodopa (MPH + LD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18046048

Group type: EXPERIMENTAL
Intervention: 400 mg oral testosterone enanthate (TE) twice daily plus 0.5 mg dutasteride daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 800 mg oral testosterone enanthate (TE) once daily plus 0.5 mg dutasteride daily
Number of subjects: 20
Study: 17057417

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Nadroparin
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Dalteparin
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (all three LMWHs)
Number of subjects: 150
Study: 15271105

Group type: EXPERIMENTAL
Intervention: Fixed combination dorzolamide-timolol (Cosopt)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Concomitant administration of 2% dorzolamide and 0.5% timolol
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Fixed combination dorzolamide-timolol (Cosopt) in replacement study
Number of subjects: 131
Study: 10746815

Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 260

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260
Study: 8698947

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Cognitive-behavior therapy
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Imipramine with clinical management
Number of subjects: 225

Group type: COMPARATOR
Intervention: Placebo with clinical management
Number of subjects: 225
Study: 1614074

Group type: EXPERIMENTAL
Intervention: Felodipine (10 mg, single oral dose)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 6540130

Group type: EXPERIMENTAL
Intervention: IgG therapy
Number of subjects: 1
Study: 3487296

Group type: EXPERIMENTAL
Intervention: Intravenous administration of verapamil prior to aortic cross‐clamping (Group 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous verapamil plus verapamil in the cardioplegic solution (Group 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Verapamil in the cardioplegic solution only (Group 3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No verapamil (Group 4)
Number of subjects: 0
Study: 30464699

Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes for physical function (pro-pf)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Objective measures of physical activity and fitness
Number of subjects: 0
Study: 27388626

Group type: EXPERIMENTAL
Intervention: 30 personalized motivational interviewing-based peer network counseling messages
Number of subjects: 200

Group type: COMPARATOR
Intervention: Attention control intervention (general health habits text messages)
Number of subjects: 200
Study: 24164779

Group type: EXPERIMENTAL
Intervention: Sucrose drinks (4 × 250 ml, total 1800 kJ/d)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Aspartame drinks (4 × 250 ml)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Sucrose drinks
Number of subjects: 41

Group type: COMPARATOR
Intervention: Sucrose drinks and Aspartame drinks
Number of subjects: 41
Study: 22646315

Group type: EXPERIMENTAL
Intervention: Group F (feedback group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Group NF (no feedback group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Group C (control group)
Number of subjects: 60
Study: 19911170

Group type: EXPERIMENTAL
Intervention: Alcohol (0.4 g/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alcohol (0.6 g/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alcohol (0.8 g/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18093708

Group type: EXPERIMENTAL
Intervention: Seated whole-body vibration (bandwidth=2-20 Hz, root-mean-squared amplitude=1.15m/s²)
Number of subjects: 21
Study: 16189197

Group type: EXPERIMENTAL
Intervention: High-dose GH (0.3 mg . kg(‐1) . d(‐1))
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: High-dose GH
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: High-dose DEXA
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lower dose DEXA
Number of subjects: 30
Study: 12939889

Group type: EXPERIMENTAL
Intervention: Computerised utility assessment interview with individualized risk assessment and decision analysis
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Information video and leaflet about high blood pressure
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 217

Group type: COMPARATOR
Intervention: Neither intervention
Number of subjects: 217
Study: 10555606

Group type: EXPERIMENTAL
Intervention: Rabeprazole
Number of subjects: 0
Study: 8554472

Group type: EXPERIMENTAL
Intervention: Roho cushion
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: PU foam cushion
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Sitting posture
Number of subjects: 14
Study: 1714507

Group type: EXPERIMENTAL
Intervention: 6-methylmercaptopurine riboside (MMPR) at 75 mg/m2
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 6-methylmercaptopurine riboside (MMPR) at 150 mg/m2
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 6-methylmercaptopurine riboside (MMPR) at 225 mg/m2
Number of subjects: 27
Study: 6134137

Group type: EXPERIMENTAL
Intervention: Bendrofluazide (5 mg)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 30446250

Group type: EXPERIMENTAL
Intervention: CPAP therapy (n=151) for 12 weeks
Number of subjects: 307

Group type: COMPARATOR
Intervention: Conservative treatment (n=156) for 12 weeks
Number of subjects: 307
Study: 28662526

Group type: EXPERIMENTAL
Intervention: Working conditions of physician assistants
Number of subjects: 26
Study: 27015720

Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy adapted for adolescents (DBT-A)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Number of subjects: 77
Study: 24768191

Group type: EXPERIMENTAL
Intervention: Extended-release niacin (ERN) 1 g/d
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Extended-release niacin with laropiprant (ERN/LRP) 1 g/20 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (washout period)
Number of subjects: 18
Study: 22878133

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Waiting list (control)
Number of subjects: 130
Study: 19892318

Group type: EXPERIMENTAL
Intervention: Single-session intervention with access to safety aids during early exposure trials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single-session intervention without access to safety aids during early exposure trials
Number of subjects: 0
Study: 18028041

Group type: EXPERIMENTAL
Intervention: Pregabalin treatment
Number of subjects: 529

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 529
Study: 16187006

Group type: EXPERIMENTAL
Intervention: Propionyl-L-carnitine (PC) 24 mg/kg b.w.
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: L-carnitine (LC) 20 mg/kg b.w.
Number of subjects: 68
Study: 11696738

Group type: EXPERIMENTAL
Intervention: 1.5% glycine
Number of subjects: 205

Group type: COMPARATOR
Intervention: 2.7% sorbitol-0.5% mannitol
Number of subjects: 205
Study: 9161626

Group type: EXPERIMENTAL
Intervention: Famciclovir 500 mg three times daily for seven days
Number of subjects: 419

Group type: COMPARATOR
Intervention: No antiviral therapy
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Famciclovir 500 mg three times daily for seven days among patients 50 years or older
Number of subjects: 419
Study: 7929515

Group type: EXPERIMENTAL
Intervention: Nonsurgical management with splint appliance (group 2, n = 8)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Commissuroplasty (group 3, n = 9)
Number of subjects: 29

Group type: COMPARATOR
Intervention: No surgery and no splint (group 1, n = 21)
Number of subjects: 29
Study: 3367744

Group type: EXPERIMENTAL
Intervention: CHO‐5
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: CHO‐6
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: CHO‐7.5
Number of subjects: 8

Group type: COMPARATOR
Intervention: WP
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: CHO trials (CHO‐5, CHO‐6, CHO‐7.5)
Number of subjects: 8
Study: 30171698

Group type: EXPERIMENTAL
Intervention: 0.03% resiquimod gel once-daily application three times per week for 4 weeks
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: 0.03% resiquimod gel seven times within 2 weeks
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: 0.03% resiquimod gel five times for 1 week
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: 0.01% resiquimod gel three times per week up to a biological end point or for a maximum duration of 8 weeks
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: 0.03% resiquimod gel three times per week up to a biological end point or for a maximum duration of 8 weeks
Number of subjects: 217

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217
Study: 28965908

Group type: EXPERIMENTAL
Intervention: Training program (theoretical and practical workshop using a phantom)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No training (Group B)
Number of subjects: 20
Study: 25833957

Group type: EXPERIMENTAL
Intervention: Daunorubicin 90 mg/m2
Number of subjects: 1206

Group type: COMPARATOR
Intervention: Daunorubicin 60 mg/m2
Number of subjects: 1206
Study: 24175460

Group type: EXPERIMENTAL
Intervention: Specific practice with a soccer ball
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Specific practice with 1 kg balls
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Variable practice with 0.35, 0.45, 0.5, and 1 kg balls
Number of subjects: 41
Study: 21151020

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Diabetes support and education (DSE)
Number of subjects: 157
Study: 19167733

Group type: EXPERIMENTAL
Intervention: Thalidomide (200 mg per day) during oral phase A
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo during oral phase A
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Thalidomide (200 mg per day) during oral phase B
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo during oral phase B
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Thalidomide and Placebo (both phases)
Number of subjects: 159
Study: 17472863

Group type: EXPERIMENTAL
Intervention: Transdermal patch
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vaginal ring
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 14641105

Group type: EXPERIMENTAL
Intervention: Folic acid 5 mg/day for 8 weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 11248742

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment at a mean dose of 0.32 mg/kg per week for 1 year
Number of subjects: 8

Group type: COMPARATOR
Intervention: Pre-treatment serum total IGF‐I levels
Number of subjects: 8

Group type: COMPARATOR
Intervention: Serum free IGF‐I levels
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Urinary IGFBPs (IGFBP‐2, IGFBP‐3, ALS)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Serum IGFBP‐3 levels
Number of subjects: 8
Study: 9134464

Group type: EXPERIMENTAL
Intervention: Primary Nursing
Number of subjects: 850

Group type: COMPARATOR
Intervention: Lagged Experimental Group (Control)
Number of subjects: 850
Study: 8201372

Group type: EXPERIMENTAL
Intervention: Hydrazine sulfate 60 mg three times per day orally
Number of subjects: 291

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 291
Study: 3251216

Group type: EXPERIMENTAL
Intervention: Faecal occult blood tests (Haemoccult)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Double contrast barium enema (DCBE)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Fibresigmoidoscopy
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Fibresigmoidoscopy and DCBE used together
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Faecal occult blood tests and DCBE alone
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Fibresigmoidoscopy and DCBE used in conjunction
Number of subjects: 154
Study: 30562088

Group type: EXPERIMENTAL
Intervention: Postintervention optical coherence tomography examination
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: 3-month follow-up optical coherence tomography examination
Number of subjects: 386
Study: 27978867

Group type: EXPERIMENTAL
Intervention: MCT diet
Number of subjects: 117

Group type: COMPARATOR
Intervention: Normal diet (control)
Number of subjects: 117
Study: 26098419

Group type: EXPERIMENTAL
Intervention: Rhodiola crenulata (RC) 250 mg twice/day (n=38)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo (250 mg twice/day) (n=19)
Number of subjects: 57
Study: 24206155

Group type: EXPERIMENTAL
Intervention: Dyad training
Number of subjects: 50

Group type: COMPARATOR
Intervention: Directed self-regulated learning (DSRL)
Number of subjects: 50
Study: 22165036

Group type: EXPERIMENTAL
Intervention: Diacetylmorphine
Number of subjects: 140

Group type: COMPARATOR
Intervention: Hydromorphone
Number of subjects: 140
Study: 19894330

Group type: EXPERIMENTAL
Intervention: Calcium 1500 g/day + alfacalcidol 0.5 mg/day
Number of subjects: 42

Group type: COMPARATOR
Intervention: Calcium 1500 g/day + placebo
Number of subjects: 42
Study: 16720058

Group type: EXPERIMENTAL
Intervention: Vinorelbine (25 mg/m2 on days 1 and 8) and cisplatin (80 mg/m2 on day 8) every 3 weeks
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Vinorelbine and cisplatin
Number of subjects: 32
Study: 15100375

Group type: EXPERIMENTAL
Intervention: Normal hemoglobin group (target hemoglobin of 14 +/- 1 g/dl)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Anemic hemoglobin group (target hemoglobin of 10 +/- 1 g/dl)
Number of subjects: 35
Study: 11529973

Group type: EXPERIMENTAL
Intervention: docetaxel (T)
Number of subjects: 283

Group type: COMPARATOR
Intervention: sequential methotrexate and 5-fluorouracil (MF)
Number of subjects: 283
Study: 8547417

Group type: EXPERIMENTAL
Intervention: Interferon alpha (1 megaunit weekly for 4 weeks)
Number of subjects: 30
Study: 2501813

Group type: EXPERIMENTAL
Intervention: 2 mg nicotine gum (Nicorette; average of 6.9 pieces per day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 40
Study: 73312

Group type: EXPERIMENTAL
Intervention: 0.1% proflavine in 100% DMSO
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 0.1% neutral red in 100% DMSO
Number of subjects: 56

Group type: COMPARATOR
Intervention: 1% picric acid in 100% DMSO (placebo)
Number of subjects: 56

Group type: COMPARATOR
Intervention: 1% color ruber in 100% DMSO (placebo)
Number of subjects: 56
Study: 30496578

Group type: EXPERIMENTAL
Intervention: Active vitamin D3 (adjusted to maintain serum 25(OH)D >75 nmol/L)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Placebo vitamin D3
Number of subjects: 260
Study: 27100724

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OT) administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0